Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1022579 | 0.99 | DPP4 (0.39) | DPP4DPP8DPP9PREPDPP7 | |
| SCHEMBL1023379 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9PREPDPP7 | |
| SCHEMBL1021006 | 0.84 | DPP4 (0.55) | DPP4DPP8DPP9PREPDPP7 | |
| Hydrochloric Acid SCHEMBL1778137 | 0.84 | DPP4 (0.54) | DPP4DPP8DPP9PREPDPP7 | |
| SCHEMBL1346883 | 0.83 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Hydrochloric Acid SCHEMBL1348449 | 0.83 | DPP4 (0.58) | DPP4DPP8DPP9PREPDPP7 | |
| SCHEMBL8268487 | 0.73 | DPP4 (0.64) | DPP4DPP8DPP9 | |
| SCHEMBL8071679 | 0.72 | DPP4 (0.65) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL6593774 | 0.71 | DPP4 (0.64) | DPP4DPP8DPP9 | |
| SCHEMBL15238181 | 0.70 | DPP4 (0.49) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | claimed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | claimed |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | claimed |
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | DPP4, DPP8, DPP3 | DPP4 1/4885DPP8 2/4885DPP9 5/4885 |
| US-20110118305-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.